- Home
- NKSH vs PLRX Comparison
NKSH vs PLRX Comparison
Compare NKSH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- PLRX
- Stock Information
- Founded
- NKSH 1891
- PLRX 2015
- Country
- NKSH United States
- PLRX United States
- Employees
- NKSH N/A
- PLRX N/A
- Industry
- NKSH Major Banks
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- PLRX Health Care
- Exchange
- NKSH Nasdaq
- PLRX Nasdaq
- Market Cap
- NKSH 172.3M
- PLRX 165.5M
- IPO Year
- NKSH N/A
- PLRX 2020
- Fundamental
- Price
- NKSH $26.67
- PLRX $1.35
- Analyst Decision
- NKSH Strong Buy
- PLRX Hold
- Analyst Count
- NKSH 1
- PLRX 10
- Target Price
- NKSH $38.00
- PLRX $9.79
- AVG Volume (30 Days)
- NKSH 7.9K
- PLRX 2.5M
- Earning Date
- NKSH 05-14-2025
- PLRX 03-03-2025
- Dividend Yield
- NKSH 5.70%
- PLRX N/A
- EPS Growth
- NKSH N/A
- PLRX N/A
- EPS
- NKSH 1.24
- PLRX N/A
- Revenue
- NKSH $44,130,000.00
- PLRX N/A
- Revenue This Year
- NKSH $1.17
- PLRX N/A
- Revenue Next Year
- NKSH $9.78
- PLRX $46.66
- P/E Ratio
- NKSH $21.89
- PLRX N/A
- Revenue Growth
- NKSH N/A
- PLRX N/A
- 52 Week Low
- NKSH $26.00
- PLRX $1.26
- 52 Week High
- NKSH $35.00
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- NKSH 41.40
- PLRX 25.56
- Support Level
- NKSH $26.76
- PLRX $1.42
- Resistance Level
- NKSH $27.90
- PLRX $1.56
- Average True Range (ATR)
- NKSH 0.60
- PLRX 0.12
- MACD
- NKSH 0.03
- PLRX 0.24
- Stochastic Oscillator
- NKSH 33.68
- PLRX 4.49
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.